BNP Paribas Financial Markets Sells 674,016 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

BNP Paribas Financial Markets decreased its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 89.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 76,772 shares of the biotechnology company's stock after selling 674,016 shares during the quarter. BNP Paribas Financial Markets' holdings in ADMA Biologics were worth $1,317,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in ADMA. Perpetual Ltd bought a new stake in shares of ADMA Biologics in the 4th quarter valued at $62,300,000. Allspring Global Investments Holdings LLC lifted its position in ADMA Biologics by 1,144.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company's stock worth $51,016,000 after acquiring an additional 2,613,482 shares during the last quarter. B Group Inc. acquired a new stake in ADMA Biologics during the fourth quarter worth approximately $39,231,000. Raymond James Financial Inc. acquired a new stake in shares of ADMA Biologics in the fourth quarter valued at approximately $19,076,000. Finally, Arrowstreet Capital Limited Partnership raised its position in shares of ADMA Biologics by 57.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 2,762,700 shares of the biotechnology company's stock valued at $47,380,000 after buying an additional 1,013,456 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company's stock.

ADMA Biologics Stock Up 2.5%

ADMA Biologics stock opened at $20.19 on Tuesday. ADMA Biologics, Inc. has a twelve month low of $9.22 and a twelve month high of $25.67. The firm has a 50 day moving average price of $20.52 and a 200-day moving average price of $18.88. The company has a market capitalization of $4.82 billion, a P/E ratio of 72.11 and a beta of 0.57. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). The company had revenue of $114.80 million for the quarter, compared to the consensus estimate of $116.40 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The firm's revenue was up 40.2% on a year-over-year basis. During the same period in the prior year, the company earned $0.08 earnings per share. As a group, equities analysts predict that ADMA Biologics, Inc. will post 0.51 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on ADMA shares. StockNews.com cut shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 price objective on shares of ADMA Biologics in a report on Tuesday, March 4th. Finally, Raymond James upped their target price on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a report on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $24.25.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.